Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | GRM8 | O00222 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25533179 | 0.80 | DPP4 (0.38) | SLC1A1DPP4DPP9LTA4HGRM8 | |
| SCHEMBL12410073 | 0.78 | TSHR (0.46) | SLC1A1TSHRKMT2AMEN1LMNA | |
| SCHEMBL16240926 | 0.78 | DPP4 (0.62) | SLC1A1TSHRKMT2AMEN1DPP4 | |
| SCHEMBL16240927 | 0.78 | DPP4 (0.62) | SLC1A1TSHRKMT2AMEN1DPP4 | |
| SCHEMBL142983 | 0.78 | SLC1A1 (0.70) | SLC1A1TSHRKMT2ALMNAKDM4E | |
| SCHEMBL23734825 | 0.78 | SLC1A1 (0.55) | SLC1A1TSHRKMT2AMEN1LMNA | |
| SCHEMBL4957051 | 0.78 | ALOX15 (0.56) | SLC1A1KMT2ADPP4DPP9GRM8 | |
| SCHEMBL6753794 | 0.78 | SLC1A1 (0.55) | SLC1A1TSHRKMT2AMEN1DPP4 | |
| SCHEMBL1666146 | 0.78 | SLC1A1 (0.70) | SLC1A1TSHRKMT2ALMNAKDM4E | |
| SCHEMBL131050 | 0.78 | SLC1A1 (0.55) | SLC1A1TSHRKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708366-B2 | Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LTD. (NZ) | 2017-07-18 | — | — | US | disclosed |
| US-9212204-B2 | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-12-15 | — | — | US | disclosed |
| EP-2928300-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | Neuren Pharmaceuticals Limited (NZ) | 2015-10-14 | — | — | EP | disclosed |
| US-20150224164-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUMATIC ACID | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-08-13 | — | — | US | disclosed |
| US-20150197543-A1 | Treatment of Autism Spectrum Disorders Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-07-16 | — | — | US | disclosed |
| WO-2014085480-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2014-06-05 | — | — | WO | disclosed |
| US-20140147491-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LIMITED (AU) | 2014-05-29 | — | — | US | disclosed |
| US-8637567-B2 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid | NEUREN PHARMACEUTICALS LTD. (NZ) | 2014-01-28 | — | — | US | disclosed |
| EP-2667715-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERES USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | Neuren Pharmaceuticals Limited (NZ) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012102832-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERES USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2012-08-02 | — | — | WO | disclosed |
| US-20110112033-A1 | COGNITIVE ENHANCEMENT AND COGNITIVE THERAPY USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-05-12 | — | — | US | disclosed |
| US-7605177-B2 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NL) | 2009-10-20 | — | — | US | disclosed |
| EP-1401808-B1 | GPE ANALOGS AND PEPTIDOMIMETICS | NEUREN PHARMACEUTICALS LTD (NZ) | 2009-07-08 | — | — | EP | disclosed |
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-12-27 | — | — | US | disclosed |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-01-04 | — | — | US | disclosed |
| US-7041314-B2 | GPE analogs and peptidominetics | NEUREN PHARMACEUTICALS LTD. (NZ) | 2006-05-09 | — | — | US | disclosed |
| EP-1401808-A4 | GPE ANALOGS AND PEPTIDOMIMETICS | NEURONZ LTD (NZ) | 2004-08-25 | — | — | EP | disclosed |
| EP-1401808-A2 | GPE ANALOGS AND PEPTIDOMIMETICS | Neuronz Limited (NZ) | 2004-03-31 | — | — | EP | disclosed |
| US-20030055004-A1 | GPE analogs and peptidominetics | NEUREN PHARMACEUTICALS LIMITED (AU) | 2003-03-20 | — | — | US | disclosed |
| WO-2002094856-A2 | GPE ANALOGS AND PEPTIDOMIMETICS | NEURONZ LIMITED (NZ) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | GRM2, GRM1, GLUL | SLC1A1 51/4885TSHR 2852/4885KMT2A 972/4885 |
| US-20030055004-A1 | GPE analogs and peptidominetics | GLUL, GCG, BAD | SLC1A1 501/4885TSHR 4233/4885KMT2A 4615/4885 |
| US-20140147491-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | GRIN2D, GRM2, GRIN2A | SLC1A1 278/4885TSHR 3954/4885KMT2A 800/4885 |
| US-20150197543-A1 | Treatment of Autism Spectrum Disorders Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid | GRIN2D, GRM2, GRIN2A | SLC1A1 275/4885TSHR 3852/4885KMT2A 845/4885 |
| US-20150224164-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUMATIC ACID | GRIN2D, GRM2, GRIK5 | SLC1A1 456/4885TSHR 3640/4885KMT2A 696/4885 |
| US-20110112033-A1 | COGNITIVE ENHANCEMENT AND COGNITIVE THERAPY USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | CHAT, GAP43, BDNF | SLC1A1 64/4885TSHR 3226/4885KMT2A 339/4885 |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | CHAT, GAP43, BCHE | SLC1A1 73/4885TSHR 3101/4885KMT2A 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.